Cytotoxic T-lymphocyte-associated protein 4 and B7 protein interface (CTLA-4–B7 interface)

The CTLA-4–B7 interface is a pivotal regulatory node in the immune system, formed by the binding of Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to its ligands, CD80 (B7-1) and CD86 (B7-2), on antigen-presenting cells (Walker & Sansom, 2011). CTLA-4 is a high-affinity receptor that outcompetes the costimulatory molecule CD28 for B7 binding, thereby delivering an inhibitory signal that halts T-cell proliferation and cytokine production (Pardoll, 2012). In oncology, this interface is targeted by checkpoint inhibitors like ipilimumab, which block the interaction to unleash a robust anti-tumor immune response (Buchbinder & Desai, 2016). Conversely, in the treatment of autoimmune diseases such as rheumatoid arthritis, the interface is modulated using CTLA-4-Ig fusion proteins like abatacept, which act as decoys to sequester B7 ligands and prevent T-cell activation (StatPearls, 2023). While highly effective, therapeutic manipulation of this interface can lead to severe immune-related adverse events due to the systemic disruption of immune tolerance (Postow et al., 2018).

Other names

CTLA-4/CD80 interfaceCTLA-4/CD86 interfaceCTLA-4:B7-1/2 complexCD152–CD80/86 interactionCTLA-4–B7-1/B7-2 interaction

Antagonistic monoclonal antibodies block the CTLA-4–B7 interaction to prevent inhibitory signaling and promote T-cell activation against tumors, while CTLA-4-Ig fusion proteins act as soluble decoys that bind B7 ligands to prevent CD28-mediated costimulation and suppress T-cell activity in autoimmune conditions.